UB
NBIX icon

UMB Bank’s Neurocrine Biosciences NBIX Stock Holding History

UMB Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Buy
1,317
+11
+0.8% +$1.63K ﹤0.01% 709
2026
Q1 		$172K Buy
1,306
+71
+6% +$9.42K ﹤0.01% 739
2025
Q4 		$175K Buy
1,235
+115
+10% +$16.7K ﹤0.01% 712
2025
Q3 		$157K Buy
1,120
+63
+6% +$8.54K ﹤0.01% 691
2025
Q2 		$133K Buy
1,057
+161
+18% +$18.5K ﹤0.01% 725
2025
Q1 		$99.1K Buy
896
+441
+97% +$55.9K ﹤0.01% 764
2024
Q4 		$62.1K Buy
455
+309
+212% +$38.2K ﹤0.01% 829
2024
Q3 		$16.8K Buy
146
+84
+135% +$11.5K ﹤0.01% 1296
2024
Q2 		$8.54K Buy
62
+38
+158% +$5.21K ﹤0.01% 1299
2024
Q1 		$3.31K Buy
+24
New +$3.28K ﹤0.01% 1426
2023
Q4 		– Sell
-2
Closed -$225 – 1698
2023
Q3 		$225 Hold
2
– – ﹤0.01% 1665
2023
Q2 		$189 Buy
+2
New +$195 ﹤0.01% 1655
2022
Q1 		– Sell
-36
Closed -$3K – 2040
2021
Q4 		$3K Buy
+36
New +$3.31K ﹤0.01% 1750

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UMB Bank's NBIX Position: Q2 2026 in Review

UMB Bank increased its Neurocrine Biosciences (NBIX) stake by 0.84% in Q2 2026, buying an estimated $1.63K and bringing the position to 1,317 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

UMB Bank first reported a position in NBIX in Q4 2021 and has held it in 13 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • UMB Bank held 1,317 shares of Neurocrine Biosciences worth $222K as of Q2 2026.
  • UMB Bank bought 11 Neurocrine Biosciences shares in Q2 2026, an estimated $1.63K.
  • Neurocrine Biosciences made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #709 holding.
  • UMB Bank first reported a position in Neurocrine Biosciences in Q4 2021 and has held it in 13 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.